Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Vita Therapeutics, a US-based startup developing cellular therapy treatments for muscular dystrophy, closed a $32m series A round on Wednesday led by its affiliate, biopharmaceutical company Cambrian Biopharma, and backed by Kiwoom Bio, SCM Life Sciences and Early Light Venture. Its technology is based on research by co-founders Douglas Falk (also its CEO) and Peter…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.